{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T21:41:23Z","timestamp":1774647683256,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.4158\/ep0362.or","type":"journal-article","created":{"date-parts":[[2010,6,23]],"date-time":"2010-06-23T00:35:04Z","timestamp":1277253304000},"page":"357-370","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Adverse Event Reporting in Patients Treated With Levothyroxine: Results of the Pharmacovigilance Task Force Survey of the American Thyroid Association, American Association of Clinical Endocrinologists, and The Endocrine Society"],"prefix":"10.1016","volume":"16","author":[{"given":"James V.","family":"Hennessey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan O.","family":"Malabanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan R.","family":"Haugen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elliot G.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP0362.OR_bb0010","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/01.ten.0000098610.80343.56","article-title":"Precise thyroxine dosing: Clinical requirements","volume":"13","author":"Hennessey","year":"2003","journal-title":"The Endocrinologist"},{"key":"10.4158\/EP0362.OR_bb0015","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1089\/thy.2006.16.1229","article-title":"Outcomes of patients with differentiated thyroid carcinoma following initial therapy","volume":"16","author":"Jonklaas","year":"2006","journal-title":"Thyroid"},{"key":"10.4158\/EP0362.OR_bb0020","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1001\/jama.1991.03470150090036","article-title":"Pseudomalabsorption of levothyroxine","volume":"266","author":"Ain","year":"1991","journal-title":"JAMA"},{"key":"10.4158\/EP0362.OR_bb0025","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1345\/aph.1A031","article-title":"Exaggerated levothyroxine malabsorption due to calcium carbonate supplementation in gastrointestinal disorders","volume":"35","author":"Csako","year":"2001","journal-title":"Ann Pharmacother"},{"key":"10.4158\/EP0362.OR_bb0030","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/0002-9343(94)90093-0","article-title":"Sucralfate causes malabsorption of L-thyroxine","volume":"96","author":"Sherman","year":"1994","journal-title":"Am J Med"},{"key":"10.4158\/EP0362.OR_bb0035","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1089\/thy.2007.0060","article-title":"New medications which decrease levothyroxine absorption","volume":"17","author":"John-Kalarickal","year":"2007","journal-title":"Thyroid"},{"key":"10.4158\/EP0362.OR_bb0040","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2753.2003.00461.x","article-title":"An evaluation of the adequacy of outpatient monitoring of thyroid replacement therapy","volume":"10","author":"Stelfox","year":"2004","journal-title":"J Eval Clin Pract"},{"key":"10.4158\/EP0362.OR_bb0045","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1210\/jc.2008-1696","article-title":"High frequency of and factors associated with thyroid hormone over-replacement and under-replacement in men and women aged 65 and over","volume":"94","author":"Somwaru","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP0362.OR_bb0050","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1089\/thy.2008.0413","article-title":"The magnitude of increased levothyroxine requirements in hypothyroid pregnant women depends upon the etiology of the hypothyroidism","volume":"19","author":"Loh","year":"2009","journal-title":"Thyroid"},{"key":"10.4158\/EP0362.OR_bb0055","doi-asserted-by":"crossref","unstructured":"Hallengren B, Lantz M, Andreasson B, Grennert L. Pregnant women on thyroxine substitution are often dysregulated in early pregnancy. Thyroid. 19:391-394.","DOI":"10.1089\/thy.2008.0206"},{"key":"10.4158\/EP0362.OR_bb0060","unstructured":"1997 Docket Number 97N-0314, Prescription Drug Products; Levothyroxine Sodium Federal Register 62: 43535-43538."},{"key":"10.4158\/EP0362.OR_bb0065","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/ncpendmet0273","article-title":"Levothyroxine dosage and the limitations of current bioequivalence standards","volume":"2","author":"Hennessey","year":"2006","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.4158\/EP0362.OR_bb0070","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1089\/105072504773297867","article-title":"Are bioequivalalence studies of levothyroxine sodium formulations in euthyroid volunteers reliable?","volume":"14","author":"Blakesley","year":"2004","journal-title":"Thyroid"},{"key":"10.4158\/EP0362.OR_bb0075","unstructured":"US Department of Health and Human Services, US Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Available at: www.fda.gov\/cder\/ob\/docs\/queryai.htm"},{"key":"10.4158\/EP0362.OR_bb0080","unstructured":"US Department of Health and Human Services, US Food and Drug Administration. Drugs@FDA Glossary of Terms. Available at: http:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ucm079436.htm#T"},{"key":"10.4158\/EP0362.OR_bb0085","unstructured":"US Department of Health and Human Services, US Food and Drug Administration. Questions and Answers on Levothyroxine Sodium Products. Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm161266.htm"},{"key":"10.4158\/EP0362.OR_bb0090","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1089\/thy.2008.0109","article-title":"The FDA revises requirements for levothyroxine products","volume":"18","author":"Burman","year":"2008","journal-title":"Thyroid"},{"key":"10.4158\/EP0362.OR_bb0095","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1001\/jama.1995.03520340064038","article-title":"Treatment guidelines for patients with hyperthyroidism and hypothyroidism","volume":"273","author":"Singer","year":"1995","journal-title":"JAMA"},{"key":"10.4158\/EP0362.OR_bb0100","series-title":"IMS National Prescription Audit","author":"IMShealth.com","year":"2009"},{"key":"10.4158\/EP0362.OR_bb0105","unstructured":"Safer JD, Hennessey JV, Braverman LE. Substituting brand name levothyroxine preparations with generics would increase treatment costs. Available at: http:\/\/www.annals.org\/cgi\/eletters\/142\/11\/891"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2041609X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2041609X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/12676PH8L4X05057.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:50:43Z","timestamp":1761515443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X2041609X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["S1530891X2041609X"],"URL":"https:\/\/doi.org\/10.4158\/ep0362.or","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse Event Reporting in Patients Treated With Levothyroxine: Results of the Pharmacovigilance Task Force Survey of the American Thyroid Association, American Association of Clinical Endocrinologists, and The Endocrine Society","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP0362.OR","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}